Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

17.01 -0.03 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 581,396
Open 16.81
Bid (Size) 17.01 (73)
Ask (Size) 17.03 (67)
Prev. Close 17.04
Today's Range 16.81 - 17.35
52wk Range 6.510 - 22.76
Shares Outstanding 58,041,410
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
The Latest Analyst Ratings for Deciphera Pharmaceuticals
 
Via Benzinga

Performance

YTD
+6.71%
+6.71%
1 Month
+6.71%
+6.71%
3 Month
+4.87%
+4.87%
6 Month
+37.40%
+37.40%
1 Year
+101.78%
+101.78%

More News

Read More
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
Via Benzinga
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Deciphera Pharmaceuticals Stock Is Nosediving
Via Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
Via Benzinga
Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients
Via Benzinga
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
Via Benzinga
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.